Alkem acquires AbbVie Inc.

Geyatee Deshpande
/ Categories: Trending, DSIJ News
Alkem acquires AbbVie Inc.

Alkem Laboratories Limited entered into an asset purchase agreement with AbbVie Inc., USA, for the acquisition of certain assets related to the active pharmaceutical ingredient (API), Dronabinol.

Assets required via the acquisition are in relation to the API Dronabinol, which includes domain names and trademarks related to ‘MARINOL’, new drug application registration with the USFDA for Marinol, logos, patents designs, know how, technical and manufacturing instructions, inventory manufacturing equipment, and other items. Post the acquisition, Alkem Laboratories will own the NDA and associated assets and will use these to commercially exploit both, branded and generic, sales in the US. Through a cash consideration, the cost of the acquisition is around US$100 million plus suitable working capital adjustments.

Based in Mumbai, Maharashtra, Alkem Laboratories is a multinational pharmaceutical company, involved in the manufacturing and selling of pharmaceutical generics, formulations, and neutraceutricals in India.

On Tuesday, the stock of the company was closed at Rs 2000.5, up by 0.55 per cent or Rs 11 per share. The 52-week high is Rs 2,149 and 52-week low is Rs 1,660.35.

Rate this article:
5.0

Leave a comment

Add comment

DSIJ MINDSHARE

Mkt Commentary28-Mar, 2024

IPO Analysis29-Mar, 2024

Expert Speak29-Mar, 2024

Mindshare29-Mar, 2024

Multibaggers28-Mar, 2024

Knowledge

General26-Mar, 2024

MF25-Mar, 2024

General18-Mar, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR